91 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
, are responsible for defending the body against not only pathogens but also abnormal cells, including cancer cells. Receptors on the surface of T cells … and decreasing to a mid-single-digit percentage if the licensed CLL-1 product candidate is in later clinical trial stages. We are also responsible
8-K
EX-1.1
qasuvdqq3h4mjl
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
4b7216
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
ganor p2emi8
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-10.1
7pn1b
6 Jul 23
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
8:01am